ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors ; volume:131 ; number:5 ; day:4 ; month:7 ; year:2024 ; pages:905-917 ; date:9.2024
British journal of cancer ; 131, Heft 5 (4.7.2024), 905-917, 9.2024

Creator: Smith, Hannah L.
Willmore, Elaine
Prendergast, Lisa
Curtin, Nicola J.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41416-024-02745-0

URN: urn:nbn:de:101:1-2411172143525.568135691805

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Smith, Hannah L.
Willmore, Elaine
Prendergast, Lisa
Curtin, Nicola J.
SpringerLink (Online service)

Other Objects (12)

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors

PARP inhibitors

Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen

Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors

PARP inhibitors

Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen

Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors

PARP inhibitors

Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen

Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors

PARP inhibitors

Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen

Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors

PARP inhibitors

Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen

Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors

PARP inhibitors

Antineoplastische Wirkung von PARP-Inhibitoren in Kombination mit ATR- oder ATM-Inhibitoren auf Ewing-Sarkomzellen

Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Related objects

Reset password